Diabetes News

HYDERABAD, India & MISSISSAUGA, Ontario--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. a global pharmaceutical company, today announced the launch of its generic Semaglutide Injection in Canada....

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced key updates to its governance structure in conjunction with its upcoming 2026 Investor Day presentation that outlines a strategic and financial vision to best position the company for future growth. “We look forward to articulating our exciting vision for growth later today at Investor Day as we seek to empower greater metabolic health through our biosensing platforms,” said Jake Leach, Dexcom’s president and CEO. “Today’s a...

PALO ALTO, Calif.--(BUSINESS WIRE)--Glooko, Inc., a global digital health company focused on helping clinicians address the growing challenges of glycemic safety and diabetes management across the care continuum, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for EndoTool IV Cloud, the first FDA-cleared, cloud-based patient-specific insulin dosing platform. EndoTool IV Cloud is the cloud-based version of EndoTool IV, Glooko’s clinical decision supp...

MADISON, Wis.--(BUSINESS WIRE)--Navitus today released its 10th annual Drug Trend Report, “Clarity for Action,” the company’s flagship annual analysis of prescription drug cost trends. The report details how utilization growth and therapeutic innovation drove prescription drug costs in 2025 and outlines clear actions for health plans and plan sponsors to counter accelerating pressure. Across the Navitus commercial book of business, net prescription drug costs increased 8.4%, up from 7% in 2024,...

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today reported its first quarter 2026 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. “This quarter, we continued to build on our developmental and clinical acc...

DENVER--(BUSINESS WIRE)--Virta Health, the leader in reversing metabolic disease, today announced new peer-reviewed research published in Endocrine Research demonstrating that its nutrition-based metabolic care model delivers broad and sustained reductions in inflammatory markers in adults with type 2 diabetes (T2D). In the study, 19 of 21 inflammatory and immune markers significantly improved after one year of treatment, with improvements largely maintained through two years. This nutrition-ba...

KONTICH, Belgium--(BUSINESS WIRE)--Flen Health Pharma NV, a Belgium-based biopharmaceutical company with more than 25 years of experience in wound and skin healing solutions, today announced that the U.S. Food and Drug Administration (FDA) has provided positive written feedback following an INTERACT (INitial Targeted Engagement for Regulatory Advice on CBER/CDER ProducTs) meeting regarding VES gel, a novel biologic designed to accelerate healing in chronic diabetic foot ulcers (DFUs). The FDA’s...

GOTHENBURG, Sweden & BURGDORF, Switzerland--(BUSINESS WIRE)--Glooko, Inc. and mylife Diabetes Care today announced an agreement to further expand their partnership, under which Glooko will serve as mylife Diabetes Care’s primary data management platform for mylife products. This next step builds on the strong, well-established collaboration between the two companies, ensuring continuity in the way healthcare professionals and patients access data from mylife products, including mylife Loop, an...

MIAMI & ROSEMONT, Ill.--(BUSINESS WIRE)--Today, the Society of Surgical Oncology (SSO), a global professional society for cancer surgeons, and OpenEvidence, the most widely used medical knowledge platform, announced a strategic partnership to strengthen access to the most trusted surgical oncology evidence at the point of care while building a foundation for innovative collaborations to support surgeons and all physicians taking care of patients with cancer. Together, SSO and OpenEvidence will...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2026 and reaffirmed financial guidance for the year ending December 31, 2026. First Quarter 2026 Financial and Strategic Highlights Achieved record first quarter pump shipments, sales and gross margin: Shipments of more than 29,000 pumps worldwide, including 19,000 pumps in the United States Sales o...